For Report Sample Contact: neeraj@kuickresearch.com
Report Weblink: https://www.kuickresearch.com/report-global-car-t-cell-therapy-market-and-clinical-trials-insight-2022.php
Table of Contents
1. Chimeric Antigen Receptor (CAR) T Cell Therapy – Next Era in Immuno Oncology
1.1 Overview
1.2 History and Development of CAR-T Technology
2. Evolution of Chimeric Antigen Receptor (CAR) T-Cell Design
2.1 Structure of CAR T Cell
2.2 1nd Generation Chimeric Antigen Receptor
2.3 2nd and 3nd Generation CAR T Cell
3. Principle of Chimeric Antigen Receptor Design
3.1 CAR Modified T Cells: Targeting
3.2 CAR Modified T Cell: Signaling
4. CAR T Cell Therapies Delivery Pipeline and Mechanism of Action
4.1 Process of CAR T Cell Therapy
4.2 Mechanism of Action
5. Approaches to Improve the CAR T Cell Therapy
5.1 Introduction
5.2 Targeting the Tumor Stroma with CAR T Cells
5.3 Targeting the Cytokine Networks
5.4 Combination Strategies for CAR T Cells
5.5 Targeting the Immune Checkpoints
6. Global CAR T Cell Therapy Clinical Trials for Cancer Treatment
6.1 Acute Lymphoblastic Leukemia
6.2 Multiple Myeloma
6.3 Brain Tumors
6.4 Lymphoma
6.5 Solid Tumors
7. Global CAR T Cell Therapies Clinical Pipeline by Company, Indication and Phase
7.1 Research
7.2 Preclinical
7.3 Clinical
7.4 Phase-I
7.5 Phase-I/II
7.6 Phase-II
7.7 Preregistration
8. Global Market Scenario of CAR T Cell Therapy
8.1 Overview
8.2 Estimated Price Analysis of CAR T Cell Therapy
9. Global Market Size of CAR T Cell Therapy
9.1 Market Share of Cancer Immunotherapy by its Technology
9.2 CAR T Cell Therapy Market Value
10. Global CAR T Cell Therapy Market Dynamics
10.1 Favorable Parameters
10.2 Challenges
11. Global CAR T Cell Therapy Market Future Prospects
12. Competitive Landscape
12.1 Autolus
12.2 Bellicum
12.3 Bluebird
12.4 Celgene
12.5 Cellectis
12.6 Celyad
12.7 Eureka Therapeutics
12.8 Fortress Biotech
12.9 Immune Therapeutics
12.10 Juno Therapeutics
12.11 Kite Pharma
12.12 Novartis
12.13 Sorrento therapeutics
12.14 TILT Biotherapeutics
12.15 Ziopharm
Figure 1-1: Historical Development of CAR T Cell Therapy
Figure 2-1: Structure of Chimeric Antigen Receptor
Figure 2-2: First Generation Chimeric Antigen Receptor
Figure 2-3: Second Generation Chimeric Antigen Receptor
Figure 2-4: Third Generation Chimeric Antigen Receptor
Figure 3-1: Targeting Mechanism of Chimeric Antigen Receptor T-Cell
Figure 3-2: Signalling Mechanism of Chimeric Antigen Receptor T Cell
Figure 4-1: Delivery Pipeline of CAR T Cell Therapy Process
Figure 4-2: CAR T Cell Therapy Mechanism of Action
Figure 5-1: Strategies to Improve CAR T Cell Therapy
Figure 6-1: CAR T Cell Therapy in Brain Tumors
Figure 6-2: Chimeric Antigen Receptor Therapy in Lymphoma
Figure 6-3: Target of Cancer Cell by Chimeric Antigen Receptor
Figure 7-1: Global andndash; CAR T Cell Therapy Clinical Pipeline by Phase (Number), 2017-2022
Figure 7-2: Global andndash; CAR T Cell Therapy Clinical Pipeline by Phase (%), 2017-2022
Figure 8-1: Adoptive T-Cell Therapy – Open Clinical Trials to Investigate the Efficacy and Safety (%), 2015
Figure 8-2: Estimated Cost of T Cell Therapy and CAR T Cell Therapy Per Patient (US$)
Figure 9-1: Cancer Immunotherapy – Market Share of by Its Technology* (%)
Figure 9-2: Global Cancer Immunotherapeutic Market (US$ Billion), 2016-2022
Figure 9-3: Global – Predictive Market of CAR T Cell Therapeutics (US$ Million), 2016-2022
Figure 10-1: Favorable Market Parameters of CAR T Cell Therapy
Figure 10-2: Challenges to Market Growth of CAR T Cell Therapy
Figure 11-1: Future Potential Immuno-Oncology
Table 3-1: Antigens which are targeted by Chimeric Antigen Receptor
Table 12-1: Clinical Pipelines of Products
